Healthcare Industry News: Barrett's esophagus
News Release - July 12, 2006
Boston Scientific Launches Radial Jaw(R) 4, Newest Version of Single-Use Biopsy ForcepsNew Jaw Configuration Designed to Yield Larger Tissue Specimens and Improve Procedural Outcomes
NATICK, Mass., July 12 (HSMN NewsFeed) -- Boston Scientific Corporation (NYSE: BSX ) today announced the U.S. launch of the newest version of its Radial Jaw® Single-Use Biopsy Forceps, featuring more jaw volume and an improved jaw design compared to the market-leading Radial Jaw 3 Forceps. Radial Jaw 4 Forceps are designed to enable collection of large high quality tissue specimens without the need to use large channel therapeutic endoscopes.
Acquiring tissue for diagnosis via biopsy is the most frequently performed procedure by gastroenterologists (GIs). In 2005, approximately 5.8 million endoscopic biopsy procedures were performed in the U.S. to diagnose various gastrointestinal diseases, including esophagitis, Barrett's esophagus, gastritis, Crohn's disease, ulcerative colitis and cancer.
The new jaw configuration of the Radial Jaw 4 Forceps is intended to provide larger tissue specimens than Radial Jaw 3 Forceps in order to facilitate tissue sample handling and preparation for accurate histological diagnosis. The forceps are also designed for consistent sample retention and enhanced passability. The Radial Jaw 4 Forceps can now extract a large tissue specimen through a 3.2mm working channel of an endoscope, as opposed to the 3.7mm working channel required with a previous version of Radial Jaw Forceps.
"Biopsies are critical for the accurate diagnosis of any gastrointestinal disorder," said Russell Yang, M.D., Keck School of Medicine, University of Southern California. "The new enhancements to Radial Jaw 4 Forceps, such as the ability to use a smaller, more common endoscope and still acquire large samples, make the Radial Jaw even more valuable for acquiring tissue to accurately diagnose a patient's condition."
"Boston Scientific is committed to providing clinicians with continuously improving technologies that advance the quality of patient care and the productivity of health care delivery," said Michael Phalen, President, Boston Scientific Endoscopy. "The introduction of the fourth generation of our market-leading biopsy forceps demonstrates this commitment, by offering an enhanced procedural experience and potentially better clinical outcomes."
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.
Source: Boston Scientific
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBoston Scientific Receives CE Mark for Next Generation WATCHMAN FLX(TM) Left Atrial Appendage Closure Device
New Four-Year Data Demonstrate Rezūm(TM) Water Vapor Therapy Offers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms
Neovasc Announces Dismissal of Claim brought by Edwards Lifesciences